DK1992697T3 - Fremstilling af TNFR-Fc - Google Patents

Fremstilling af TNFR-Fc

Info

Publication number
DK1992697T3
DK1992697T3 DK08005732.6T DK08005732T DK1992697T3 DK 1992697 T3 DK1992697 T3 DK 1992697T3 DK 08005732 T DK08005732 T DK 08005732T DK 1992697 T3 DK1992697 T3 DK 1992697T3
Authority
DK
Denmark
Prior art keywords
tnfr
preparation
Prior art date
Application number
DK08005732.6T
Other languages
English (en)
Inventor
Denis Drapeau
James R Mercer
Wenge Wang
Yen-Tung Luan
Daniel R Lasko
Original Assignee
Wyeth Res Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1992697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Res Ireland Ltd filed Critical Wyeth Res Ireland Ltd
Application granted granted Critical
Publication of DK1992697T3 publication Critical patent/DK1992697T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08005732.6T 2004-08-27 2005-08-26 Fremstilling af TNFR-Fc DK1992697T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60537904P 2004-08-27 2004-08-27
EP05791482A EP1781802B1 (en) 2004-08-27 2005-08-26 Production of a tnfr-ig fusion protein

Publications (1)

Publication Number Publication Date
DK1992697T3 true DK1992697T3 (da) 2010-05-17

Family

ID=35500648

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08005732.6T DK1992697T3 (da) 2004-08-27 2005-08-26 Fremstilling af TNFR-Fc
DK05791482.2T DK1781802T3 (da) 2004-08-27 2005-08-26 Fremstilling af et TNFR-Ig-fusionsprotein

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05791482.2T DK1781802T3 (da) 2004-08-27 2005-08-26 Fremstilling af et TNFR-Ig-fusionsprotein

Country Status (37)

Country Link
US (1) US7300773B2 (da)
EP (2) EP1992697B1 (da)
JP (3) JP2008511330A (da)
KR (1) KR100988451B1 (da)
CN (2) CN101061231B (da)
AR (2) AR050537A1 (da)
AT (2) ATE446376T1 (da)
AU (1) AU2005280036B2 (da)
BR (1) BRPI0514694B8 (da)
CA (1) CA2578138C (da)
CL (1) CL2017000577A1 (da)
CR (2) CR8998A (da)
CY (2) CY1109721T1 (da)
DE (2) DE602005020076D1 (da)
DK (2) DK1992697T3 (da)
EC (1) ECSP077354A (da)
EG (1) EG26922A (da)
ES (2) ES2341390T3 (da)
GT (2) GT200500233A (da)
HN (1) HN2005000485A (da)
HR (2) HRP20100011T1 (da)
IL (1) IL181588A (da)
MX (1) MX2007002381A (da)
MY (1) MY137803A (da)
NO (1) NO344785B1 (da)
NZ (1) NZ579208A (da)
PE (2) PE20100448A1 (da)
PL (2) PL1781802T3 (da)
PT (2) PT1992697E (da)
RS (2) RS51255B (da)
RU (1) RU2458988C2 (da)
SI (2) SI1992697T1 (da)
SV (1) SV2006002211A (da)
TW (1) TWI364458B (da)
UA (1) UA89383C2 (da)
WO (1) WO2006026447A2 (da)
ZA (1) ZA200701672B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
KR101495549B1 (ko) * 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
US8192951B2 (en) * 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
CA2668771C (en) * 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
RU2009132986A (ru) * 2007-03-02 2011-04-10 Уайт (Us) Применение меди и глутамата в культуре клеток для производства полипептидов
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP5576115B2 (ja) 2007-04-26 2014-08-20 中外製薬株式会社 高濃度アミノ酸含有培地を用いた細胞の培養方法
EP2310523B1 (en) * 2008-04-17 2015-06-10 Wyeth LLC Methods for enhanced production of bone morphogenetic proteins
JP2011516086A (ja) * 2008-04-18 2011-05-26 上海中信国健薬業股▲ふん▼有限公司 濃縮培養液及びその使用方法
WO2010016943A2 (en) * 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
CA2795461C (en) 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
BR112012027434B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Processo para produção de um polipeptídeo recombinante compreendendo uma fase de produção
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
AU2011329053A1 (en) 2010-11-15 2013-06-06 Biogen Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
CA2852021C (en) * 2011-10-21 2018-08-28 Pfizer Inc. Addition of iron to improve cell culture
JP2015509714A (ja) * 2012-02-22 2015-04-02 エヌヴィーアイピー プロプライエタリー リミテッド 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201507875RA (en) 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
DK3351620T3 (da) * 2013-10-11 2020-10-26 Regeneron Pharma Metabolsk optimeret cellekultur
WO2015116820A1 (en) 2014-01-30 2015-08-06 Coherus Biosciences, Inc. Perfusion media
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) * 2015-03-20 2016-07-20 广东东阳光药业有限公司 一种cho细胞收获液的前处理方法
KR20240093910A (ko) * 2015-04-01 2024-06-24 베링거 인겔하임 인터내셔날 게엠베하 세포 배양 배지
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CN110484487A (zh) * 2019-08-21 2019-11-22 安徽欣乐生物技术有限公司 一种适用于cho细胞培养用无蛋白培养基及其培养方法
JP2024503239A (ja) 2020-12-22 2024-01-25 アムジェン インコーポレイテッド 細胞培養法
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
CN114480492B (zh) * 2022-01-28 2023-04-21 景泽生物医药(合肥)股份有限公司 一种重组人抗体融合蛋白的制备方法
CN119510778A (zh) * 2024-12-31 2025-02-25 北京同立海源生物科技有限公司 一种高稳定性的pdgf-bb活性检测方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
DE68925971T2 (de) * 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
ES2312569T3 (es) 2001-04-30 2009-03-01 Eli Lilly And Company Anticuerpos humanizados.
ES2318006T3 (es) 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP4429728B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta

Also Published As

Publication number Publication date
HK1121497A1 (en) 2009-04-24
CR20120560A (es) 2012-12-04
ECSP077354A (es) 2007-05-30
ES2341390T3 (es) 2010-06-18
UA89383C2 (ru) 2010-01-25
CR8998A (es) 2007-11-23
EP1781802B1 (en) 2009-10-21
HN2005000485A (es) 2009-06-09
HK1099941A1 (en) 2007-08-31
DE602005020076D1 (de) 2010-04-29
WO2006026447A3 (en) 2006-04-20
BRPI0514694B1 (pt) 2019-04-24
NZ579208A (en) 2012-01-12
IL181588A0 (en) 2007-07-04
BRPI0514694A (pt) 2008-06-17
PL1992697T3 (pl) 2010-08-31
HRP20100011T1 (hr) 2010-02-28
US20060121569A1 (en) 2006-06-08
CY1110092T1 (el) 2015-01-14
ZA200701672B (en) 2012-04-24
EG26922A (en) 2014-12-25
TW200619388A (en) 2006-06-16
KR100988451B1 (ko) 2010-10-18
WO2006026447A2 (en) 2006-03-09
GT200500234A (es) 2006-10-10
HRP20100271T1 (hr) 2010-06-30
CL2017000577A1 (es) 2017-12-01
GT200500233A (es) 2006-03-09
PE20060815A1 (es) 2006-09-14
RU2458988C2 (ru) 2012-08-20
PT1781802E (pt) 2010-01-04
TWI364458B (en) 2012-05-21
NO344785B1 (no) 2020-04-27
CA2578138A1 (en) 2006-03-09
RS51072B (sr) 2010-10-31
JP2012095672A (ja) 2012-05-24
CN101061231B (zh) 2012-09-26
IL181588A (en) 2010-12-30
CA2578138C (en) 2010-10-05
AU2005280036A1 (en) 2006-03-09
SI1992697T1 (sl) 2010-07-30
SI1781802T1 (sl) 2010-01-29
AU2005280036B2 (en) 2011-11-03
PE20100448A1 (es) 2010-06-22
JP5921910B2 (ja) 2016-05-24
ATE446376T1 (de) 2009-11-15
CN102876761A (zh) 2013-01-16
SV2006002211A (es) 2006-10-04
PT1992697E (pt) 2010-04-21
EP1781802A2 (en) 2007-05-09
ATE461285T1 (de) 2010-04-15
ES2335518T3 (es) 2010-03-29
RS51255B (sr) 2010-12-31
US7300773B2 (en) 2007-11-27
PL1781802T3 (pl) 2010-03-31
EP1992697A1 (en) 2008-11-19
BRPI0514694B8 (pt) 2021-05-25
AR050537A1 (es) 2006-11-01
CN101061231A (zh) 2007-10-24
MX2007002381A (es) 2007-06-15
AR088824A2 (es) 2014-07-10
JP2008511330A (ja) 2008-04-17
DK1781802T3 (da) 2010-01-25
CY1109721T1 (el) 2014-08-13
RU2007108717A (ru) 2008-10-10
EP1992697B1 (en) 2010-03-17
KR20070069140A (ko) 2007-07-02
WO2006026447A9 (en) 2006-06-01
JP2016056214A (ja) 2016-04-21
MY137803A (en) 2009-03-31
DE602005017285D1 (da) 2009-12-03
NO20071570L (no) 2007-05-23

Similar Documents

Publication Publication Date Title
DK1802579T3 (da) Derivater af 3-arylaminopyridin
ATE461285T1 (de) Herstellung von tnfr-fc
DK2363414T3 (da) Stedstyret modifikation af FVIII
DK1778618T3 (da) Syntese af triethylentetraminer
DK1877568T3 (da) Hydrolysering af arabinoxylan
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1720866T3 (da) Fremgangsmåde
DK1831154T3 (da) Fremstilling af pregabalin og relaterede forbindelser
DK1636190T3 (da) Stabilt krystal af 4-oxoquinolinforbindelse
DK1745062T3 (da) Forbedrede modulatorer af koagulationsfaktorer
DK1791820T3 (da) Enantioselektiv fremstilling af quinolinderivater
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DK1937071T3 (da) Krystallinske modifikationer af pyraclostrobin
DK1931315T3 (da) Depotformuleringer af nalbufin
DK1710245T3 (da) Krystalform af asenapinmaleat
DK1879844T3 (da) Fremstilling af natriumdiformiat
DK1940465T3 (da) Ny anvendelse af anti-IL-1beta-antistoffer
NO20043305D0 (no) Preparation of lodixanol
DK1827483T3 (da) Terapeutiske formuleringer af keratinocyt-vækstfaktor
NO20055643D0 (no) Preparation of lodixanol
DK1763520T3 (da) Anvendelse af trisubstituerede benzopyranoner
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK2275098T3 (da) Hidtil ukendte orale formulationer af ospemifen
DK1794111T3 (da) Fremgangsmåde til fremstilling af cyclopentanon
DK2301576T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer